Tag Archives: NASDAQ:STML

A Director at Stemline Therapeutics (NASDAQ: STML) is Buying Shares

Yesterday, a Director at Stemline Therapeutics (STML – Research Report), Alan S. Forman, bought shares of STML for $10.29K. Following this transaction Alan S. Forman’s holding in the company was increased by 1.16% to a total of $847.7K. See today’s

Stemline Therapeutics (STML) Received its Third Buy in a Row

After H.C. Wainwright and Wedbush gave Stemline Therapeutics (NASDAQ: STML) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Boris Peaker maintained a Buy rating on Stemline Therapeutics today. The company’s shares

Stemline Therapeutics (STML) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Stemline Therapeutics (STML – Research Report) today and set a price target of $35.00. The company’s shares closed last Monday at $9.25, close to its 52-week low of $7.82. According

Cowen & Co. Maintains a Buy Rating on Stemline Therapeutics Inc (STML)

In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Stemline Therapeutics Inc (STML – Research Report). The company’s shares closed last Monday at $9.96. According to TipRanks.com, Peaker is a 1-star analyst with

Analysts Are Bullish on These Healthcare Stocks: Stemline Therapeutics Inc (STML), Alimera (ALIM)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Stemline Therapeutics Inc (STML – Research Report), Alimera (ALIM – Research Report) and Immunomedics (IMMU – Research Report) with bullish sentiments. Stemline

Cowen & Co. Maintains Their Buy Rating on Stemline Therapeutics Inc (STML)

In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Stemline Therapeutics Inc (STML – Research Report). The company’s shares closed last Monday at $10.52. According to TipRanks.com, Peaker is a 1-star analyst with